Sheng-Jiun Wu
Overview
Explore the profile of Sheng-Jiun Wu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
595
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boucher L, Prinslow E, Feldkamp M, Yi F, Nanjunda R, Wu S, et al.
MAbs
. 2023 Apr;
15(1):2195517.
PMID: 37074212
Single-chain fragment variable (scFv) domains play an important role in antibody-based therapeutic modalities, such as bispecifics, multispecifics and chimeric antigen receptor T cells or natural killer cells. However, scFv domains...
2.
DeAngelis N, Ferrante C, Powers G, Sendecki J, Mattson B, Pizutti D, et al.
Cancer Chemother Pharmacol
. 2022 Mar;
89(4):515-527.
PMID: 35298699
Purpose: Preclinical characterization of cetrelimab (JNJ-63723283), a fully humanized immunoglobulin G4 kappa monoclonal antibody targeting programmed cell death protein-1 (PD-1), in human cancer models. Methods: Cetrelimab was generated by phage...
3.
Van Kolen K, Malia T, Theunis C, Nanjunda R, Teplyakov A, Ernst R, et al.
J Alzheimers Dis
. 2020 Sep;
77(4):1397-1416.
PMID: 32894244
Background: As a consequence of the discovery of an extracellular component responsible for the progression of tau pathology, tau immunotherapy is being extensively explored in both preclinical and clinical studies...
4.
Nair-Gupta P, Diem M, Reeves D, Wang W, Schulingkamp R, Sproesser K, et al.
Blood Adv
. 2020 Mar;
4(5):906-919.
PMID: 32150609
CD33 is expressed in 90% of patients with acute myeloid leukemia (AML), and its extracellular portion consists of a V domain and a C2 domain. A recent study showed that...
5.
Tam S, McCarthy S, Armstrong A, Somani S, Wu S, Liu X, et al.
Antibodies (Basel)
. 2019 Sep;
6(3).
PMID: 31548527
Engineering of fragment crystallizable (Fc) domains of therapeutic immunoglobulin (IgG) antibodies to eliminate their immune effector functions while retaining other Fc characteristics has numerous applications, including blocking antigens on Fc...
6.
Fursov N, Lu J, Healy C, Wu S, Lacy E, Filer A, et al.
Mol Immunol
. 2016 Jun;
75:178-87.
PMID: 27294560
The cell-surface receptor ST2L triggers cytokine release by immune cells upon exposure to its ligand IL-33. To study the effect of ST2L-dependent signaling in different cell types, we generated antagonist...
7.
Moores S, Chiu M, Bushey B, Chevalier K, Luistro L, Dorn K, et al.
Cancer Res
. 2016 May;
76(13):3942-53.
PMID: 27216193
Non-small cell lung cancers (NSCLC) with activating EGFR mutations become resistant to tyrosine kinase inhibitors (TKI), often through second-site mutations in EGFR (T790M) and/or activation of the cMet pathway. We...
8.
Malia T, Teplyakov A, Ernst R, Wu S, Lacy E, Liu X, et al.
Proteins
. 2016 Jan;
84(4):427-34.
PMID: 26800003
Microtubule-associated protein tau becomes abnormally phosphorylated in Alzheimer's disease and other tauopathies and forms aggregates of paired helical filaments (PHF-tau). AT8 is a PHF-tau-specific monoclonal antibody that is a commonly...
9.
Santulli-Marotto S, Wheeler J, Lacy E, Boakye K, Luongo J, Wu S, et al.
Monoclon Antib Immunodiagn Immunother
. 2015 Dec;
34(6):373-80.
PMID: 26683175
CCL22 inactivation in vivo occurs by cleavage at the N-terminus; however, it is unclear whether this encompasses the entire site of CCR4 interaction. CCL17 also binds CCR4 and its function...
10.
Santulli-Marotto S, Boakye K, Lacy E, Wu S, Luongo J, Kavalkovich K, et al.
PLoS One
. 2013 Dec;
8(12):e81465.
PMID: 24339934
CCL17 (TARC) function can be completely abolished by mAbs that block either one of two distinct sites required for CCR4 signaling. This chemokine is elevated in sera of asthma patients...